welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
not yet recruiting

Safety Study of BLS-M22 in Healthy Volunteers

key information

study id #: NCT03789734

condition: Muscular Dystrophy, Duchenne

status: not yet recruiting


BLS-M22 is being developed as an anti-myotatin agent for the treatment of Duchenne Muscular Dystrophy (Muscular Dystrophy). A total of 37 subjects participated in this study to confirm the safety of BLS-M22.

intervention: BLS-M22, Placebo

mechanism of action: Anti-myostatin to promote muscle growth

results: https://clinicaltrials.gov/ct2/show/results/NCT03789734

last updated: January 16, 2019

study details

start date: March 2019

estimated completion: October 2019

phase of development: Phase 1

size / enrollment: 37

study description:
This study is a dose Block-randomized, Double-blind, Placebo-controlled and Dose-escalation Phase I Clinical Trial to Evaluate Safety of BLS-M22.
The single ascending dose group participated in 9 patients in each group(500mg, 1000mg, 2000mg/BLS-M22 or Placebo(n=7:2)). The multiple ascending dose group participated in 10 patients(determined dose in SAD/BLS-M22 or Placebo(n=8:2)).

primary outcomes:

  • Adverse events [ Time Frame: up to 4-5 weeks ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

secondary outcomes:

  • AUClast [ Time Frame: From 0 hours to 24 hours ]
    Evaluation of the pharmacokinetic properties after administration of BLS-M22
  • Immunogenicity(Myostatin specific IgG level in serum) [ Time Frame: up to 4-5 weeks ]
    Evaluation of the immunogenicity after administration of BLS-M22

inclusion criteria:
• Male and female subjects between 19-55 years of age
• BMI: 19~28kg/m2(male), 18~25kg/m2(female) at screening test
• Able to provide consent to participate and having signed an Informed Consent Form (ICF)
• The subjects can obey the demands of the scheme

exclusion criteria:
• Subject has a clinically significant disease or history of liver, kidney, cardiovascular system, endocrine system, musculoskeletal system, digestive system, respiratory system, neuropsychiatry, blood tumor system.
• Hypersensitive to the lactobacillus-containing food (such as yogurt) and the lactobacillus preparation and the investigational drug
• Subject has received an investigational drug or a bioequivalence study drug within 90 days of the randomization
• Subject has received steroids or other immunosuppressive drugs within 30 days of randomization
• Positive serum test results for hepatitis C virus, hepatitis B virus, HIV or syphilis
• Those who do not use of a medically acceptable method of contraception during the trial, or who plan to provide sperm
• Pregnant women
• Subject has genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
• Subject has abnormal clinical laboratory test results
• Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study

study contacts

sponsor: BioLeaders Corporation

contacts: Cho Rong Park, +82312809646 ext +82312809646, crpark@bioleaders.co.kr

investigators: Jae Hyung Lee

locations: Korea Republic of